DGAP-News: Sernova Corp.
/ Key word(s): Study results/Study
05.01.2022 / 15:25
The issuer is solely responsible for the content of this announcement.
LONDON, ONTARIO – January 5, 2022 – Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that new interim results from the ongoing safety, tolerability and efficacy Phase I/II clinical trial of Sernova’s Cell Pouch(TM) will be released on January 10, 2022.
Originally, it was planned that Dr. Piotr Witkowski, principal investigator of Sernova’s Phase I/II clinical trial would present an update in a poster session at the American Society of Transplant Surgeons (ASTS) 22nd Annual “State of the Art” Winter Symposium on January 13, 2022, but the conference was postponed yesterday until the end of July 2022 because of the ongoing COVID-19 pandemic.
“We are pleased to be announcing these new interim data earlier than anticipated in conjunction with the J.P. Morgan conference which is one of the premier international healthcare conferences,” said Dr. Philip Toleikis, President & CEO of Sernova.
ABOUT THE J.P. MORGAN HEALTHCARE CONFERENCE
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community. The J.P. Morgan 40th Annual Healthcare Conference (JPM 2022) will take place virtually, January 10-13, 2022.
Sernova is developing regenerative medicine therapeutic solutions using a medical device (Cell Pouch) and immune protected therapeutic cells / tissues (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through cellular production of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease.
The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago. Positive initial results have been presented at several international scientific conferences.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corey Davis, Ph.D.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|700 Collip Circle, Ste 114|
|N6G 4X8 London|
|EQS News ID:||1265221|
|End of News||DGAP News Service|